{"document_type": "article", "byline": {"contributor": "Andrew Pollack contributed reporting.", "person": [{"role": "reported", "firstname": "Matthew", "organization": "", "rank": 1, "lastname": "GOLDSTEIN"}], "original": "By MATTHEW GOLDSTEIN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Turing Pharmaceuticals founder Martin Shkreli is served subpoena to appear before House Committee on Oversight and Government Reform to discuss pricing trends and other developments in drug industry; it is unclear whether Shkreli, who has been charged with securities fraud, will show up to testify.", "multimedia": [{"type": "image", "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "legacy": {"wide": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "legacy": {"xlarge": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "447"}, "width": 600, "subtype": "xlarge", "height": 447}, {"type": "image", "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "Congress Calls Shkreli to Testify on Rapid Rises in Drug Pricing", "main": "Congress Calls Martin Shkreli to Testify on Rapid Rises in Drug Pricing"}, "print_page": "2", "keywords": [{"value": "Turing Pharmaceuticals AG", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Shkreli, Martin (1983- )", "is_major": "Y", "rank": "2", "name": "persons"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "House Committee on Oversight and Government Reform", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Securities and Commodities Violations", "is_major": "N", "rank": "6", "name": "subject"}], "snippet": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "source": "The New York Times", "lead_paragraph": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "word_count": "848", "pub_date": "2016-01-21T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/01/21/business/dealbook/congress-subpoenas-martin-shkreli-over-drug-prices.html", "_id": "569fe66a38f0d80627b20ab9"}